ArticleKorean journal of ophthalmology : KJO2026
Effectiveness of Ultrathin 40-Gauge Needles for Intravitreal Injections.
Article in Korean journal of ophthalmology : KJO, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare pain perception and immediate post‑procedural complications of intravitreal injections (IVIs) performed with conventional 30‑gauge needles versus ultrathin 40‑gauge needles.
methodsThis single-center, retrospective crossover study reviewed consecutive patients who underwent serial IVIs for neovascular age-related macular degeneration, diabetic macular edema, retinal vein occlusion, myopic choroidal neovascularization, or other indications between April and October 2020. Each patient received one injection with a 30‑gauge needle and one with a 40‑gauge needle-either to the fellow eye on the same day or to the same eye 1-month apart. Injections (0.05 mL bevacizumab, ranibizumab, or aflibercept) were administered in an operating room by a single surgeon following the guidelines of Avery et al. Pain was recorded immediately postinjection on a visual analog scale (VAS). Subconjunctival hemorrhage (SCH) and vitreous reflux (VR) were graded 0 to 4.
resultsMean age was 69.3 ± 11.5 years; 69.0% were men. VAS pain scores were significantly lower with 40‑gauge needles than with 30‑gauge needles (2.33 ± 1.26 vs 4.02 ± 1.73; paired difference [mean ± standard error], -1.69 ± 0.33; p < 0.001). Median VR grade declined from 2 (interquartile range [IQR], 2-3) to 0 (IQR, 0-1) with 40‑gauge needles (p < 0.001). SCH grade did not differ between gauges (median [IQR], 0 [0-1]; p = 0.928). No injection-related adverse events occurred.
conclusionsUsing an ultrathin 40‑gauge needle for IVIs significantly reduces patient‑reported pain and VR without increasing subconjunctival hemorrhage. These findings support the integration of 40‑gauge needles into routine IVI practice to enhance long-term patient adherence and treatment efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.